Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 527

1.

Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma.

Baues C, Görgen H, Semrau R, Nast-Kolb B, Assenmacher K, Celik E, Morgenthaler J, Rosenbrock J, Trommer-Nestler M, Houbois C, Kobe C, Kriz J, Engert A, Marnitz S.

Leuk Lymphoma. 2019 Jun 22:1-7. doi: 10.1080/10428194.2019.1623888. [Epub ahead of print]

PMID:
31232136
2.

Treatment of elderly Hodgkin lymphoma patients.

Engert A.

Hematol Oncol. 2019 Jun;37 Suppl 1:92-94. doi: 10.1002/hon.2590. No abstract available.

PMID:
31187519
3.

Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials.

Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A.

Ann Oncol. 2019 May 27. pii: mdz168. doi: 10.1093/annonc/mdz168. [Epub ahead of print]

PMID:
31132094
4.

Controversies in the Treatment of Classical Hodgkin Lymphoma.

Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A.

Hemasphere. 2018 Oct;2(5):e149. doi: 10.1097/HS9.0000000000000149. Epub 2018 Oct 2.

5.

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma.

Borchmann S, Engert A.

Oncotarget. 2018 Dec 25;9(101):37462-37463. doi: 10.18632/oncotarget.26486. eCollection 2018 Dec 25. No abstract available.

6.

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group.

Bröckelmann PJ, Müller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezek H, Balakumaran A, Raut MK, Engert A, von Tresckow B.

Ann Oncol. 2019 Mar 1;30(3):490-491. doi: 10.1093/annonc/mdz004. No abstract available.

PMID:
30657863
7.

Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.

Sud A, Thomsen H, Law PJ, Försti A, da Silva Filho MI, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Lightfoot T, Kane E, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Nat Commun. 2019 Jan 8;10(1):157. doi: 10.1038/s41467-018-08105-w.

8.

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.

Sasse S, Reddemann K, Diepstra A, Borchmann S, Oschlies I, Schnitter A, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e45-e46. doi: 10.3324/haematol.2018.207829. No abstract available.

9.

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.

Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG).

Br J Haematol. 2019 Apr;185(1):42-52. doi: 10.1111/bjh.15741. Epub 2018 Dec 28.

PMID:
30592027
10.

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Kreissl S, Goergen H, Müller H, Meissner J, Mehnert A, Bürkle C, Fuchs M, Engert A, Behringer K, Borchmann P.

Leuk Lymphoma. 2019 Jun;60(6):1389-1398. doi: 10.1080/10428194.2018.1540781. Epub 2018 Dec 3.

PMID:
30507313
11.

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.

PMID:
30347469
12.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
13.

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.

Sud A, Thomsen H, Orlando G, Försti A, Law PJ, Broderick P, Cooke R, Hariri F, Pastinen T, Easton DF, Pharoah PDP, Dunning AM, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N, Campa D; PRACTICAL Consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Blood. 2018 Nov 8;132(19):2040-2052. doi: 10.1182/blood-2018-06-855296. Epub 2018 Sep 7.

14.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B.

Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.

PMID:
30168134
15.

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.

Blood. 2018 Nov 22;132(21):2273-2279. doi: 10.1182/blood-2018-05-852129. Epub 2018 Aug 30.

PMID:
30166329
16.

Hodgkin Lymphoma in Adults.

Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N.

Dtsch Arztebl Int. 2018 Aug 6;115(31-32):535-540. doi: 10.3238/arztebl.2018.0535.

17.

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).

Borchmann S, Müller H, Haverkamp H, Baues C, Marková J, Hüttmann A, Glunz A, Fuchs M, Borchmann P, Engert A.

Leukemia. 2019 Feb;33(2):439-446. doi: 10.1038/s41375-018-0240-8. Epub 2018 Aug 21.

PMID:
30131583
18.

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e21-e24. doi: 10.3324/haematol.2018.196279. Epub 2018 Aug 3. No abstract available.

19.

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.

PMID:
30064977
20.

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18.

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.

Ann Oncol. 2018 Sep 1;29(9):1926-1931. doi: 10.1093/annonc/mdy250.

PMID:
30010775

Supplemental Content

Loading ...
Support Center